Key takeaways
Zeposia (ozanimod) and Rebif (interferon beta-1a) are both used to treat relapsing forms of multiple sclerosis (MS), but they have some key differences. Zeposia is taken orally once a day, while Rebif is an injectable medication that you need to take three times a week. Zeposia is a synthetic medication that works by blocking white blood cells from leaving your lymph nodes, which helps reduce inflammation. On the other hand, Rebif is a biologic that affects cell processes, though its exact mechanism for treating MS isn't fully understood. Zeposia can also treat moderate-to-severe ulcerative colitis (UC), whereas Rebif is only approved for MS. Common side effects of Zeposia include infections and changes in liver tests, while Rebif often causes flu-like symptoms and injection site reactions. Both medications can increase the risk of liver damage and serious infections. Zeposia can also cause dangerously slow heart rate, high blood pressure, and breathing problems, while Rebif can increase the risk of seizures. Both medications are only available by brand name.
